Management of extracranial arteriovenous malformations of the head and neck by Fernández-Alvarez, Veronica et al.
ARTICLE IN PRESS 
JID: ANL [mNS; December 17, 2019;21:4 ] 
Auris Nasus Larynx xxx (xxxx) xxx 
Contents lists available at ScienceDirect 
Auris Nasus Larynx 
j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / a n l 
Management of extracranial arteriovenous malformations of the 
head and neck ✩ 
Veronica Fernández-Alvarez a , ∗, Carlos Suárez b , c , Remco de Bree d , Iain J. Nixon e , 
Antti A. Mäkitie f , g , h , Alessandra Rinaldo i , Jonathan Downer j , Alfio Ferlito k 
a Vascular Surgery Department, Hospital Torrecárdenas, Almería, Spain 
b Instituto de Investigación Sanitaria del Principado de Asturias and CIBERONC, ISCIII, Oviedo, Spain 
c Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, Oviedo, Spain 
d Department of Head and Neck Surgical Oncology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The 
Netherlands 
e Departments of Surgery and Otolaryngology, Head and Neck Surgery, Edinburgh University, Edinburgh, UK 
f Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 
Finland 
g Research Programme in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland 
h Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and 
Karolinska Hospital, Stockholm, Sweden 
i University of Udine School of Medicine, Udine, Italy 
j Department of Clinical Neurosciences, Edinburgh University, UK 
k Coordinator of the International Head and Neck Scientific Group, Italy 
A R T I C L E I N F O 
Article history: 
Received 26 August 2019 
Accepted 2 December 2019 
Available online xxx 
Keywords: 
Congenital vascular anomaly 
Arteriovenous malformation 
High-flow vascular malformation 
Hemangioma 
Superselective embolization 
A B S T R A C T 
The purpose of this study was to review the outcomes of the different therapies for extracranial 
head and neck arteriovenous malformations (AVMs). 
AVMs are high-flow congenital vascular anomalies. They are composed of a complex system of 
vessels directly connecting feeding arteries to draining veins forming a nidus. 
They may be potentially life-threatening due to progressive symptoms and infiltrative disease. 
Extracranial AVMs most commonly affect the head and neck area (47.4%) followed by the 
extremities (28.5%). AVMs are best characterized as being either focal or diffuse. Focal AVMs 
have good outcomes following adequate treatment. Diffuse lesions have multiple feeding vessel, 
which results in high rates of recurrence despite treatment. 
The management of AVMs includes conventional surgery and endovascular techniques. A com- 
bination of embolization and surgical resection has become the treatment of choice over the last 
years. The main goal of both forms of treatment being the complete blockage or resection of 
the nidus. Transcatheter embolization of vessels has evolved over the years and new embolic 
agents have emerged. The types of materials available for embolization are classified into me- 
chanical devices, liquid agents and particulates. Efficacy, rate of recurrence and most common 
complications were evaluated. 
AVMs recurrence after embolization or resection is reported in up to 80% of cases. Incomplete 
resection and embolization can induce aggressive growth of the remaining nidus and the risk of 
progression is up to 50% within the first 5 years and recurrences can occur up to 10 years later. 
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h  1. Introduction 
Vascular malformations are rare vascular anomalies com-
posed of inappropriately connected vasculature. Any blood
vessel type, or a combination of them, can be affected in a
vascular malformation. 
Mulliken and Glowacki first proposed a classification of
vascular anomalies in 1982 based on histology. This classifi-
cation was accepted by the International Society for the Study
of Vascular Anomalies (ISSVA) in 1992. Vascular anoma-
lies were divided into tumors, like hemangiomas (caused
by an endothelial cell proliferation) and vascular malforma-
tions (caused by a development of abnormal vascular chan-
nels). The most common vascular malformations include lym-
phatic malformations (LMs), capillary-venular malformations
(CMs), venous malformations (VMs) and arteriovenous mal-
formations (AVMs). Furthermore, they were subdivided based
on the flow characteristics into high-flow (AVMs) and low-
flow lesions (LMs, CMs and VMs) [1] . 
Arteriovenous malformations (AVMs) of the head and neck
are high-flow congenital vascular anomalies. They are com-
posed of a complex system of vessels directly connecting
feeding arteries to draining veins forming a nidus. The nor-
mal capillary network is lacked. AVMs are considered as the
most dangerous subtype of vascular malformation because
they may be potentially life-threatening attributing to progres-
sive symptoms and infiltrative disease [2 , 3] . They have diverse
clinical presentations and are complex to manage due to high
rates of recurrence irrespective of therapeutic approach. The
classification and management of AVMs have considerably
changed in the last few years. Endovascular treatment is cur-
rently almost always part of the treatment of AVMs often
combined with surgical resection. However, in many cases,
treatment is only palliative [4] . A multidisciplinary approach
is recommended for optimization of patient outcomes, espe-
cially in pediatric AVMs in which treatment and timing of
intervention must be individualized [5] . 
2. Epidemiology 
The prevalence of AVM is not well known but in hospital-
based autopsy data it ranges from 5 to 613/100,000 [6] .
They are uncommon vascular malformations representing
only 1.5% of all vascular anomalies [4 , 7] . Over 90% ofPlease cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008  associated with the highest degree of cure and permanent occlusion,
 reported was 48%. Other materials, such as cyanoacrylate, have
plete remission, while the reported rates of complete regression of
Polyvinyl alcohol are above 50%. At present, there are no unified
lic agent. 
y approach is recommended to support decision making about the
 to achieve optimal outcome. A long-term post-treatment follow-up
e early recurrence. 
logical Society of Japan Inc. Published by Elsevier B.V. All rights
reserved.
VMs occur intracranially [8] . Although the exact incidence
s unknown, Visser et al. have shown that extracranial AVMs
ere present in only 4.7% of the 1131 patients with vascular
nomalies referred to their Vascular Anomalies centre over a
4-year period [9] . Extracranial AVMs most commonly affect
he head and neck area (47.4%) followed by the extremities
28.5%) [10] . It has been reported that 50% of the head and
eck AVMs affect the oral and maxillofacial region [4 , 7] . In
 retrospective review of 81 patients with an AVM of the
ead and neck, Kim et al. reported that cheek was the most
ommon site (31%) followed by ear (16%) [11] . Race or
ex predilection has not been demonstrated, [5 , 12] although
preafico et al. have reported a male:female ratio of 1:1.5
13] . 
. Classification 
AVMs are best characterized as being either focal or dif-
use. Focal AVMs appear as a soft tissue mass usually diag-
osed during infancy or childhood. They have a single arterial
eeder and well-defined borders and a nidus. Focal AVMs
ave good outcomes following adequate treatment. In con-
rast, diffuse AVMs cross and usually destroy tissue bound-
ries. They are more frequently discovered in older children
nd adults. Diffuse lesions have multiple feeding vessels that
ake successful treatment more challenging, requiring vigi-
ant follow-up and repeated interventions [5 , 3 , 14 , 15] . 
The Schobinger classification is the most used system
or clinical AVM characterization according to their natural
ourse of progressive disease Table 1 . It was introduced at
he International Society for the Study of Vascular Anoma-
ies (ISSVA) meeting in 1990 [16] . 
AVMs have also been staged based upon disease quies-
ence (stage I), active or palpable growth (stage II), soft tissue
estruction (stage III) or associated heart failure (stage IV).
ue to the variability of the disease, further modifications
ere proposed by Richter and Suen to include the number of
ervicofacial subunits involved and depth of invasion [17] . 
. Natural history and clinical features 
AVMs are detected at birth in 40% of cases [18] . They
an be identified as a hypervascular blush and are often mis-
iagnosed as birthmarks or “hemangiomas”. However, unlike
emangiomas, AVMs are typically progressive, and sponta-, Management of extracranial arteriovenous malformations of the head and 
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Stage I Quiescence. 
Asymptomatic. Cutaneous pink blush, warmth 
Stage II Expansion. Active growth. 
Same as stage I plus enlargement, pulsations, thrill, bruit 
and tortuous veins 
Stage III Destruction. 
Same as stage II plus either dystrophic skin changes, 
ulceration, tissue necrosis, persistent pain, bleeding, 
disfigurement 
Stage IV Decompensation. 
Same as stage III plus cardiac failure 
Table 2 
Magnetic resonance appearance of major vascular anomalies. 
High Enhancement Low Enhancement 
Intermediate T2 signal Hemangioma AVM 































u  eous regression is extremely rare. To date there have been
o reported cases of spontaneous regression of AVMs. He-
angiomas are usually not present at birth and generally ap-
ear suddenly during the early neonatal period as a rapidly
rowing tumor. Hemangiomas show an initial rapid growth
uring the early proliferate phase followed by slow regres-
ion through the long involution phase, generally resolving
pontaneously before reaching the age of 7–9 years. 
Although these lesions are congenital, they usually grow
uring adolescence and become clinically apparent in adult-
ood. Liu et al. have demonstrated that the average age
t which AVMs progresses is 12.7 years ( + / −11 years)
15] . 
The trigger for their expansion is still not completely un-
erstood. Hormonal changes (puberty, pregnancy and hor-
one therapy), trauma, infection, or iatrogenic causes (biop-
ies, surgery, embolization) are considered potential growth
riggers that stimulate progression and aggravate morbidity
19] . However, Liu et al. did not find progression in pregnant
others with quiescent lesions [15] . 
On physical examination, AVMs may show local erythema
nd hyperthermia with prominent pulsations, a palpable thrill
nd an audible bruit [20] . It is important to understand that the
rteriovenous shunting that characterizes AVMs may have sig-
ificant hemodynamic impact, often leading to reduced cap-
llary oxygenation, ischemia, local hypervascularity, vascular 
teal phenomenon and increased venous pressure. These can
esult in destruction of soft and bony tissue, pain, ulcera-
ion, gangrene, dangerous hemorrhage, esthetic deformity and
unctional deficits when the malformation reaches a signifi-
ant size. Though uncommon, congestive heart failure is also
 possible complication of AVMs. 
. Etiology and pathogenesis 
The etiology and pathogenesis of AVMs remain unclear
lthough they are suggested to result from a disturbance in
ascular development during the 4–6th weeks of gestation
16] . This is thought to be caused by a failure of the arte-
iovenous channels to undergo apoptosis or to regress in the
rimitive retiform plexus. These nonfunctioning shunts are
ater canalized to form small arteriovenous connections that
ilate, cause local ischemia, and subsequently enter a cycle
f vascular collateralization and recruitment. 
Studies of cerebral AVMs have identified the involvement
f the vascular endothelial growth factor (VEGF) and platelet-
erived growth factor (PDGF). However, it is unclear if patho-
hysiological mechanisms for cerebral and extracranial AVMs
re identical [21] . Increased levels of factors involved in
ascular destabilization, such as angiopoeitin-2 and matrix
etalloproteinase-9, and reduced levels of vascular stabiliz-
rs (angiopoeitin-1, integrin, and metalloproteinase inhibitors)
ave also been found in AVMs [22 , 5] . AVMs are usually iso-
ated findings, however, a genetic predisposition for AVMs
an be found in several clinical syndromes, such as hered-
tary hemorrhagic telangiectasia (HHT, mutations in ENG,
CVRL1 and SMAD4 genes affecting the TGF-beta signaling
athway), capillary-malformation-arteriovenous malformation Please cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008 CM-AVM, mutation in RASA1 gene), CLOVES syndrome
somatic mutation in PIK3CA) and PTEN hamartoma tumor
yndrome (mutation in PTEN gene) [18,23] . 
. Diagnosis 
AVM diagnosis is clinical and based on history and phys-
cal examination with additional imaging characteristics. In
eneral, spontaneous, nontraumatic bleeding from a vascular
nomaly in an older child suggests the presence of an AVM
5] 
.1. Pathology 
AVMs’ histology reveals numerous arteriovenous shunts 
nd dilated capillary beds with a combination of loosely
rouped capillaries, arterioles, and venules within a fibromyx-
matous background. The vessels are typically tortuous, are
eficient in smooth muscle and have poor interendothelial
unctions. AVMs are characterized by thick-walled arteries
nd arterialized thick-walled veins, which have the inherent
otential to grow and recruit new blood vessels [23] . 
.2. Imaging 
Radiological imaging confirms the diagnosis, maps the le-
ion, shows the possibilities and route of endovascular treat-
ent, identifies associated anomalies and provides surveil-
ance of disease and response to therapy. Table 2 shows a
implified MRI-based diagnostic algorithm that can be used
o differentiate between the most common vascular lesions
able 2 . Table 3 summarizes the imaging features of heman-
ioma and AVM Table 3 . [24] . 
Ultrasonography with color Doppler is widely available
nd useful in evaluating the clinical suspicion of an AVM
f accessible and it can be used as an inexpensive modality to
ssess disease progression and treatment outcomes. Doppler
ltrasonography images show a network of multiple arteries, Management of extracranial arteriovenous malformations of the head and 
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US High-velocity low-resistance arterial flow and pulsatile flow 
in venous drainage 
Multilobular mass with distinct margins 
CT Enlarged feeding and draining vessels 
Osseous overgrowth 
Hypervascular with large internal and feeding and draining 
vessels 
MRI Enlarged feeding and draining vessels 
Tissue is permeated by vascular flow voids 
Mild enhancement and T2 hyperintensity reflect tissue 
edema 
Proliferative phase: 
Avid enhancement and only moderate T2 hyperintensity 
reflecting hypercellularity on MRI Involuting phase: 
Progressive diminution in enhancement with increasing 
fatty component 










































f  with increased diastolic flow, dilated blood vessels and arte-
rialized draining with a biphasic waveform. 
Computed tomography angiography (CTA) and magnetic
resonance angiography (MRA) define the morphology, nidus,
and supportive vasculature of AVMs more accurately than
other modalities and is less invasive than conventional an-
giography. CTA is important for delineating bone involve-
ment (overgrowth and/or lysis). However, repeated CTAs add
unwanted radiation exposure in the pediatric population. On
angiography AVMs appear as multiple, enlarged, enhancing,
feeding arteries filling a cluster of grapelike structures cor-
responding to the nidus with rapid contrast shunting from
feeding arteries to draining veins. 
MRA may delineate the lesion better than CT because it
provides superior tissue contrast resolution. AVMs character-
istically appear as enlarged vascular channels, with dilated
feeding and draining vessels and no discrete soft-tissue mass.
These high-flow vessels have bright signal intensity in flow-
enhanced gradient echo images and appear as multiple flow
voids in T2-weighted spin echo sequence ( Fig. 1 ). 
Digital Subtraction Angiography (DSA) is the gold stan-
dard for diagnosis and characterization of an AVM because
it provides the best spatial and temporal resolution to study
vascular anatomy. DSA is an invasive procedure that shouldPlease cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008 e considered only for treatment planning. The classic angio-
raphic appearance of an AVM consists of multiple enlarged
eeding arteries rapidly shunting into a nidus and then into
ilated draining veins. A superselective catheterization helps
o delineate the feeding vessels and the nidus. 
. Management 
The treatment of AVMs remains challenging especially in
iffuse lesions, which results in high rates of recurrence de-
pite treatment. The current management of AVMs includes
onventional surgery and endovascular techniques, with the
ain goal of both forms of treatment being the complete re-
ection or the complete block of the nidus. Partial treatment
an induce aggressive growth of the remaining nidus leading
o worsening disease [5 , 8 , 16] . 
Based on nidal morphology and in order to provide better
uidance, Cho et al. proposed an angiographic classification
ystem for a therapeutic approach to AVMs, which provides
redictive information in terms of clinical outcome [25] . Ac-
ording to their work AVMs were divided into four subtypes
able 4 . As reported by Cho et al., type I and type II mal-
ormations were the most curable lesions. Types IIIa and IIIb, Management of extracranial arteriovenous malformations of the head and 
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Table 4 
Angiography classification system of AVM. 
Type I Arteriovenous 
fistulae 
Three or less arteries shunting to 
one draining vein 
Type II Arteriolovenous 
fistulae 
Multiple arteries shunting to one 
draining vein 
Type III Arteriolovenulous 
fistulae 
Multiple arteries shunting to 
multiple veins 
Type IIIa – with nondilated fistula 














































Figure 2. Left ECA angiogram showing an extracranial AVM nidus fed pri- 


































w  ere more difficult to treat and prone to higher failure and
ecurrence rates. 
Surgical treatment of AVM in the head and neck, espe-
ially in the upper aerodigestive tract, is particularly difficult
ecause of the complex anatomy of the region. Surgical lig-
tion or embolization of the proximal arteries should not be
erformed because the lesion will develop collateral arterial
eeders that will make endovascular treatment of the lesion
ore difficult and also the obliteration of these arteries can
lock further embolizations [16 , 20] . Success of selective em-
olization depends on local vascular anatomy and chance of
ollateralization. However, this is often unsuccessful as a sin-
le treatment method for these high-flow lesions since recruit-
ent of arteries from surrounding tissue is likely to occur. In
hese cases, maximum safe embolization followed by direct
or short-term) surgical resection is the recommended treat-
ent. However, this treatment strategy may be associated with
erious complications and extensive morbidity and negative
mpact on quality of life. 
A combination of embolization and surgical resection has
ecome the treatment of choice over the last years. 
.1. Surgery 
Surgery should aim for complete resection of the nidus,
inimizing functional loss and preservation of aesthetics. In
he past, surgical monotherapy of AVMs was more popular
han interventional therapy or combined therapy [20] . Nowa-
ays, surgical resection is a good choice for localized AVMs,
n which complete removal can be performed with minimal
urgical bleeding and well-defined borders [8] . Preoperative
uperselective embolization of the lesion is recommended and
hould be performed 24–48 h prior to surgery. This approach
elps to minimize intraoperative bleeding. Nonstick bipolar
autery and gel foam with thrombin are important intraopera-
ive tools to control bleeding. Lastly, immediate reconstruction
ay be necessary which may require local, regional, or mi-
rovascular free flaps. The recurrence rate after microvascular
ree flap reconstruction may be low, because highly vascular-
zed free flaps may regulate and even reverse postoperative
hanges in the vascularization and fibrosis of the surgically
reated area potentially leading to an ischemic environment
hich would facilitate the development of neovasculature by
eans of sprouting and non-sprouting angiogenesis. A mi-
rovascular free flap may stabilize hemodynamics surround-
ng the AVM by interrupting the vicious cycle of ischemia
25] . Patients with AVMs that are difficult to delineate byPlease cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008 maging are not good candidates for resection and should be
onsidered for alternative therapies. 
.2. Endovascular treatment 
Endovascular treatment can be performed using a transarte-
ial approach, direct percutaneous puncture of the nidus, or a
etrograde transvenous approach. Cho et al. reported that type
I and type IIIb lesions had better results with transvenous
pproach or direct puncture while type IIIa lesions were usu-
lly only reachable by a transarterial approach [26] . However,
avos et al. and also Meila et al. preferred the transarterial
oute as the first choice although in cases with severe tortuos-
ty or proximal occlusion from prior embolization or surgical
rocedures, they performed direct puncture [27 , 28] ( Figs. 2–5 )
Intravascular embolization of AVMs can be used as a sin-
le modality therapy with a success rate of about 65% for
omplete closure of extracranial AVMs. Extremely large or
iffuse AVMs with great risk of surgical morbidity are also
easonable candidates for embolization alone [5] . In addition,
mbolization alone can be considered as palliation for tem-
orary disease control. AVM is not a static lesion clinically,
t progresses over time [15] . As a result of that, several ses-
ions of embolization may be required to provide therapeutic
ffect on AVMs [23 , 26 , 28] . Le Fourn et al. performed 66
mbolizations in 31 patients reaching devascularization rate
reater than 75% of the initial levels in 56.3% of the pa-
ients, as well as symptomatic improvement in 72%. For 13
VMs that required 2 or more embolizations, the mean inter-
al between procedures was 18.7 + /– 28.5 months (median:
.5 months) [29] . Meila performed 86 embolizations with a
ean number of procedures of 6.1 per patient reaching a
omplete angiographically confirmed closure of the AVM in
0% of the patients [28] . On the other hand, Liu et al. re-
orted in a study with 272 patients that the rate of recurrence
as 14.2 times greater in patients undergoing embolization, Management of extracranial arteriovenous malformations of the head and 
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Figure 3. Angiographic injection confirming intranidal needle position after 
direct percutaneous placement under ultrasound guidance. 
Figure 4. Direct percutaneous injection of PHIL 25% liquid embolic under 















Figure 5. Final left ECA angiogram showing complete nidal occlusion fol- 



































T  alone versus resection (with or without embolization). Un-
fortunately, multiple embolizations have not yet been shown
to lower the rate of recurrence. In fact, Liu et al. demon-
strated that repeated embolization did not reduce the recur-
rence rate, which was 97.7% after a single treatment, 98.2%
after two embolizations and 99.1% following three or more
treatments. Similarly, the recurrence rate was not reduced af-
ter multiple resections (with or without embolization) [15] .
However, in a few children with diffuse and expanding dis-
ease, serial embolizations (every 3 months) has been effective
to control deep lesions [5] . Additionally embolization can re-
place a disfiguring pulsatile lump with a lump of embolic
agent. So even if complete nidal occlusion is achieved, sur-
gical resection may be preferred to optimize cosmetic result o
Please cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008 nd eliminate risk of recurrence. If left in situ, particularly
round buccal mucosa erosion and ulceration can occur over
ime exposing subcutaneous embolic agent. Surgical resection
ollowing embolization can help prevent this. 
The types of materials available for embolization are clas-
ified into mechanical devices (coils), liquid agents (absolute
thanol, n-butyl cyanoacrylate, ethylene-vinyl alcohol copoly-
er, precipitation hydrophobic inyectable liquid and fibrin
lue) and particulates (polyvinyl alcohol). 
Transcatheter embolization of vessels has evolved over the
ears and new embolic agents have emerged. Embolization
onsists of intravascular injection of an inert agent, in order
o occlude blood flow. A successful embolization requires oc-
lusion of the nidus of the AVM, sparing the normal arterial
ranches supplying adjacent areas. An arteriogram is initially
erformed to delineate the vessel selected to be embolized. A
ide variety of catheters with different shapes are useful for
aining access to the nidus. The microcatheter is advanced to
 location as close to the nidus as possible. Then the coil, or
iquid embolic agent can be introduced under fluoroscopy to
nsure accurate deployment. A postembolization arteriogram
hould be performed through the catheter or sheath to ex-
lude residual feeding vessels. If heparin was administered
efore embolization, then complete vessel occlusion may not
e immediately seen on the final images. 
Embolization is stopped by considering the duration of
he procedure, the local side effects and the volume of the
mbolic agent injected. The decision to perform a new em-
olization is linked to the clinical efficacy of the treatment,
he recurrence of symptoms, the technical difficulties of a
ew embolization and the possibility of surgical excision
23 , 26 , 29] 
Flow reduction techniques can be used to increase the
oncentration of the embolic agent within the AVM nidus.
his can be performed using balloon catheters to temporarily
cclude the arterial inflow or venous outflow. For some le- 
, Management of extracranial arteriovenous malformations of the head and 
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c  ions external compression during the procedure may be fea-
ible. 
.2.1. Coils 
Vascular coils consist of a metallic device to occlude blood
essels. Multiple different configurations of coils are avail-
ble. The diameter of the coil should be oversized by 10%–
0% of the vessel diameter to prevent distal migration after
lacement which is the major complication. If the coil is un-
ersized, it will be free floating when placed in the artery. 
The coil is radiopaque and can be visualized well using
uoroscopy. An angiographic catheter is placed at the site in-
ended for coil placement. A guidewire tip is used to advance
he coil through the catheter. Under fluoroscopic visualiza-
ion, the delivery wire is advanced until the entire length of
he coil exits the distal end of the catheter. Immediately upon
xiting the catheter, the coil begins to twist. 
Usually, multiple coils are often necessary. As the coils
re being placed, the tip of the catheter may be used to tamp
own or to bunch up to compact the coils. This helps to create
 good plug to serve as a nidus for thrombus formation and
cclusion. 
After coil placement is complete, a completion arteriogram
s performed to check out an adequate vessel occlusion. 
Habitually coils are used in large calibre high flow compo-
ents or fistulous parts of an AVM nidus. They can be used
efore liquid embolic agents such as Onyx to reduce flow or
o provide plug formation of the dominant feeding branch like
nferior alveolar artery or internal maxillary artery in cases of
andibular AVMs [13 , 27 , 30] . 
.2.2. Absolute ethanol 
Alcohol has historically been the primary agent used ex-
racranially and therefore, it is one of the agents most often
sed for embolization of peripheral AVMs [18] . For small
VMs, which are fed by only one or two main arteries, a
uccessful outcome is possible with superselective emboliza-
ion of the nidus. The most common complications reported
ith alcohol include skin and peripheral nerve injury. Less
ommon complications include cardiopulmonary collapse, 
nd-organ damage, and renal failure [31] . Sclerosant dilution,
isdirection and nontarget effect are common difficulties
ecause high-flow and collateral flow of AVMs may dilute
nd redirect the ethanol, preventing it from acting in the
argeted area for sufficient time to ensure optimal action [23] .
he maximum recommend volume is 1.0 mL/kg, however
ason and colleagues suggested the dose should be reduced
o 0.5 mL/kg given the increased serum alcohol levels and
otential negative side effects. 
In a retrospective review of absolute alcohol use in soft
issue AVMs involving a series of 32 patients (142 total ses-
ions), Shin et al. concluded that dose limitations of less than
.5–1 mg/kg and a maximum dose per injection of 10 mL
o not cause an overall increase in pulmonary artery pressure
32] . 
In a series of 66 AVMs, Cho et al. found alcohol most
ffective for type II (85%), and type IIIb (83%) than for
ype IIIa or mixed types (50%). They considered that ethanolPlease cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008 mbolization was effective in 74% (32% cured and 42%
ith partial remission). The overall complication rate was
8% [26] . Su et al. reported comparable results with 84%
f patients effectively controlled with 100% of the AVMs
eing devascularized after absolute ethanol embolization with
 minor complication rate of 24% [33] . Park et al. reported
 series of 176 patients treated with ethanol embolization.
verall, 68 patients (39%) were cured, 91 patients (52%)
howed a partial response, 9 patients (5%) showed no re-
ponse, treatment failed (in terms of a inaccessible lesion,
erminated treatment schedule as a result of an expected
omplication or no therapeutic effect despite treatment) in 7
atients (4%), and treatment aggravated the condition in one
atient (1%). The overall complication rate was 45% with
 35% rate of minor complications and 10% rate of major
omplications [34] . Lower cure rates were reported by Do
t al. in a series of extremity AVMs involving bone. Forty
atients with inoperable AVMs in the body and extremities
nderwent staged ethanol embolizations and it was consid-
red effective in 68% patients (40% cured and 28% with
artial remission). Fifteen percent of procedures resulted
n minor complications (skin and transient peripheral nerve
njuries) and 3% resulted in major complications [35] . 
Dabus et al. concluded that of all embolic agents, ethanol
eems to be associated with the highest degree of cure and
ermanent occlusion. However, owing to its known compli-
ations, it should be used by physicians experienced in the
se of this agent [27] . Many interventionalists find alcohol to
ave great risks, including injury to adjacent normal tissues,
articularly mucosal surfaces, skin and neurologic tissue, with
he potential for cardiopulmonary collapse caused by escape
o the right side of the heart and pulmonary bed. 
.2.3. Cyanoacrylate 
N–butyl cyanoacrylate (n-BCA) belongs to a group of ad-
esive glues. In the presence of blood, it polymerizes and
orms a cast, which adheres to the vessel wall. Cyanoacrylate
s a clear substance, so it needs to be mixed with Lipiodol
o provide radio-opacity during fluoroscopic injection. The
mount of Lipiodol mixed with the n-BCA controls the rate
f polymerization. Therefore, the dilution ratio is determined
y rate of blood flow and by the depth to which penetration of
lue is desired. To prevent polymerization within the catheter,
% dextrose in water (D5W) is infused before the injection.
he use of a coaxial catheter system is highly recommended
o allow for a more secure catheter position. Also, in case of
lue around the microcatheter tip, maneuvers to release it are
asier and safer to perform. To inject the glue a three-way
topcock can be used to allow flushing of the catheter with
5W solution between pulses of glue injection (“sandwich
echnique”). This reduces the risk of microcatheter retention
nd allows for control of the amount and depth of penetration
f n-BCA [36] . 
Advantages of this technique include short time to em-
olization, low rate of same-vessel recanalization, and the
bility to penetrate vascular beds in a flow-directed fash-
on. Complications of its use include pulmonary embolism,
atheter retention, formation of a glue mass that can be a, Management of extracranial arteriovenous malformations of the head and 
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c  source of infection, tissue erosion, muscle dysfunction, tran-
sient local pain with erythema and swelling due to the in-
flammatory reaction after the procedure [37] . 
There are limited reports in the literature describing its use
in peripheral AVMs. Nevertheless n-BCA has been mostly
used for embolization of cerebral AVMs [38] . The largest
series has been reported by Kitagawa et al. with 23 patients
and 29 embolizations using nBCA and lipiodol where the aim
of the embolization was slowing down the flow to perform
a polidocanol sclerotherapy after the treatment. The rate of
effective results was 87%, with 9% complete remission and
78% partial remission. No major complications occurred but
2 localized arterial thromboses and non-healing skin ulcers
were seen in 2 patients [37] . 
7.2.4. Polyvinyl alcohol (Onyx) 
“Onyx” is an ethylene vinyl alcohol copolymer (EVOH)
mixed with a solvent (dimethyl sulfoxide or DMSO). Polymer
precipitation occurs once it comes in contact with an aqueous
solution. The solvent diffuses out, leaving a polymeric solid
outer cast around the tip of the microcatheter acting as a
backstop to allow the mixture to be pushed into the AVM
(“plug and go” technique). 
The benefits of Onyx compared with n–butyl cyanoacry-
late are that it is not an adhesive agent and thus, it can be
injected over a long period of time, allowing for complete
nidal penetrance without risk of catheter adherence. The use
of detachable tip microcatheters allows greater reflux and
longer injection time. Onyx can also be injected using a direct
percutaneous access needle (DMSO compatible). Some of
the downsides of Onyx are its expensive cost, increased use
of continuous fluoroscopy, and significant post -intervention
artifact seen on CT imaging. Onyx contain suspended mi-
cronized tantalum powder for visualization under fluoroscopy.
This results in a black vessel cast, which may lead to skin
discoloration. Complications of its use include pulmonary em-
bolism, catheter retention, nerve injury and skin discoloration.
Reports of its use have mostly involved embolization of
cerebral AVMs. There are a few small case series on its use
in peripheral AVMs. Thiex et al. demonstrated effective treat-
ment of 18 cervical-facial AVMs using Onyx (71 procedures).
Transient swelling and local tenderness were seen in 7 pa-
tients but there were no serious complications or skin tattoo-
ing in their series [39] . 
Arat et al. used Onyx to treat 3 craniofacial AVMs with
total removal in 2 cases (one combined with surgery and an-
other small one with onyx alone). In both, the complication
was retention of the catheter tip. The third case had residual
AVMs and refused more embolization sessions. One patient
had skin discoloration [40] . 
Giurazza et al. recently reported a series of 16 patients,
with a total of 38 procedures of transarterial embolization of
peripheral high-flow AVM with Onyx. A technical success
was obtained in 11 patients; at 30-day of follow-up, 15 pa-
tients showed improvements in symptoms, even those with
incomplete embolization; however, after almost 1 year from
treatment accomplishment, 7 patients (44%) showed relapsePlease cite this article as: V. Fernández-Alvarez, C. Suárez and R. de Bree et al.
neck, Auris Nasus Larynx, https:// doi.org/ 10.1016/ j.anl.2019.11.008 f symptoms and presented with radiological signs of AVM
ecurrence. No clinically relevant complications occurred [41] .
Dabus et al. treated 12 patients with symptomatic periph-
ral AVMs with Onyx. A complete occlusion was obtained in
0% of the patients and the other 50% showed a mild resid-
al AVM on arteriography within a mean follow-up period of
0 months. One episode of skin ulceration was seen [27] . 
Meila et al. reported that prolonged and repeated Onyx in-
ections within the same AVM pedicle are possible and allow
t to be pushed more distally toward and within the nidus
28] . 
.2.5. Precipitation hydrophobic injectable liquid (PHIL) 
Precipitation hydrophobic injectable liquid polylactide-co-
lycolide and plyhydroxyethylmethacrylate (PHIL) is a novel
iquid embolic agent used in fistulas and AVMs. PHIL, like
nyx consists of an EVOH copolymer dissolved in DMSO,
ut for fluoroscopy purposes it has an iodine component cova-
ently bonded to the EVOH copolymer instead of suspended
icronized tantalum powder. Therefore, PHIL is white in-
tead of black, while preserving other properties of EVOH
opolymers such as its softer consistency after precipitation.
urthermore, the absence of a metallic component leads to
 more homogenic radiodensity during embolization, reduces
rtifacts at follow-up imaging and should reduce the risk of
icrocatheter blockage. 
Veld reported the use of PHIL on the management of a
mall auricular AVM fed by branches of the external carotid
rtery. After the nidus was filled with embolic agent, the AVM
id not decrease in size, which may be considered a cosmetic
ownside of this technique. However, skin color reverted to
ormal improving its cosmetically appealing characteristics.
eld described the reduced skin discolouration as an advan-
age of this agent [42] . 
.2.6. Fibrin glue 
Fibrin Glue (Tisseal) is a liquid fibrin sealant composed of
uman fibrinogen, plasma, and thrombin. It is typically used
or surgical hemostasis or tissue sealing. However, Chen et
l. used fibrin glue combined with OK-432 (picibanil) and
ingyangmycin in 18 AVMs of the face and neck and re-
orted good outcomes. Twelve lesions (67%) completely in-
oluted, 4 (22%) mostly and 2 (11%) partially involuted. The
ollow-up period ranged from 6 to 12 months. None of the
atients presented with hematologic toxic effects or signs of
ulmonary involvement [43] . 
One of the risks of glues and liquid fibrin injection is that
he delivery of the agent is not well controlled, and non-target
essels may be at risk for embolization. De Luca et al. de-
cribed a “glue lung” in a boy with a complex Galen vein
rteriovenous malformation. During the angiographic proce-
ure, some of the colloidal glue suddenly embolized into the
ulmonary vascular bed [44] . 
.2.7. Polyvinyl alcohol particles (PVA) 
Polyvinyl Alcohol Particles are made from a polyvinyl al-
ohol foam sheet that is vacuum dried and rasped into parti-
les. They provide permanent occlusion by adherence to the, Management of extracranial arteriovenous malformations of the head and 
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essel. The results are an inflammatory reaction and focal
ngionecrosis, with vessel fibrosis developing over time. 
The major disadvantage of PVA particles is their ten-
ency to aggregate, occluding vessels more proximally than
ight be expected based on stated size. Particle clumping
an cause catheter occlusion and they can also accumulate in
he catheter hub and theoretically cause subsequent nontarget
mbolization when the catheter is flushed [45] . 
In a retrospective review 10 patients with extensive cer-
icofacial AVMs were treated only with PVA embolization.
esidual or recurrent disease required revision surgery in 8
atients [17] . Bhandari treated 14 patients with facial AVMs
sing PVA. In 90–100% of the cases devascularisation was
chieved and the lesions were resected 24–48 h after the em-
olisation. There were no embolisation-related complications 
ith polyvinyl alcohol and no recurrence in 6 months [46] . 
. Conclusions 
AVMs should be differentiated from other vascular lesions
uch as hemangiomas based on their clinical and radiological
eatures. AVMs can be considered focal or diffuse and clas-
ification systems are available both to describe their growth
attern and angiographic appearance. These classifications are
seful not only for comparing results between centers but as
n aid to select individualized therapy and prognosis. 
Different therapies have been reported for head and neck
VMs in the literature. However, there is a limited amount
f studies evaluating its efficacy and therefore, there are no
lobally agreed guidelines. 
In small isolated AVMs with a clearly defined feeding ves-
el and without bony involvement, surgical monotherapy may
e the first option for primary treatment. For more exten-
ive lesions or previously treated AVMs the combination of
uperselective embolization and surgery leads to better in-
raoperative management and results in the highest success
ates. However, recurrence after embolization or resection is
eported in up to 80% of cases [10] . Incomplete resection and
mbolization can induce aggressive growth of the remaining
idus and the risk of progression is up to 50% within the first
 years [8 , 20 , 28 , 29] . Recurrences can occur up to 10 years
ater and thus, a long-term post-treatment follow-up is rec-
mmended to detect recurrence [17] . Therefore, an interdis-
iplinary treatment approach is crucial in making decisions
bout the best therapeutic approach and achieving optimal
utcome. 
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